Aging Populations And Digital Patient Care Will Boost Vascepa Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
17 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
CA$9.51
45.1% undervalued intrinsic discount21 Aug
CA$5.22
1Y
68.4%7D
2.9%